Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
about
Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.Bcl-2 family in non-small cell lung cancer: its prognostic and therapeutic implications.Evolution of In Silico Strategies for Protein-Protein Interaction Drug DiscoveryBH3 mimetics induce apoptosis independent of DRP-1 in melanoma
P2860
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Safety, efficacy, and pharmaco ...... ts with advanced solid tumors.
@en
type
label
Safety, efficacy, and pharmaco ...... ts with advanced solid tumors.
@en
prefLabel
Safety, efficacy, and pharmaco ...... ts with advanced solid tumors.
@en
P2093
P2860
P1476
Safety, efficacy, and pharmaco ...... ts with advanced solid tumors.
@en
P2093
Anthony W Tolcher
Carol Ann Vanderwal
Guinan Lian
Jennifer Arzt
Kyle D Holen
Lee S Rosen
Niki S Rudersdorf
Patricia LoRusso
Todd A Busman
Whitney Kirschbrown
P2860
P2888
P304
P356
10.1007/S00280-015-2883-8
P577
2015-09-29T00:00:00Z
P6179
1012512633